D-0450-2025 Class II Ongoing
FDA drug recall D-0450-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Feb 28, 2025 and is designated Class II. Reason for recall: CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit The recall status is ongoing. Affected quantity: 84,048 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 4, 2025
- Initiation Date
- Feb 28, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 84,048 bottles
Product description
Carvedilol Tablets USP 12.5 mg, 500-Count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-164-05
Reason for recall
CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
Distribution pattern
U.S. Nationwide
Code information
Lot, Exp: Lots 19231899, 19231922, 19231927, 19231967, 19231979, Exp Apr-25; Lots 19232226, 19232234, 19232265, 1923227,1 Exp May-25; Lots 19232758, 19232759, 19232762, 19232788, Exp Jun-25
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0450-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026